Anti-CXCL11 antibody [EPR21755-173]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(3 Publications)
Rabbit Recombinant Monoclonal CXCL11 antibody. Suitable for IP, WB and reacts with Human samples. Cited in 3 publications.
View Alternative Names
ITAC, SCYB11, SCYB9B, CXCL11, C-X-C motif chemokine 11, Beta-R1, H174, Interferon gamma-inducible protein 9, Interferon-inducible T-cell alpha chemoattractant, Small-inducible cytokine B11, IP-9, I-TAC
- IP
Supplier Data
Immunoprecipitation - Anti-CXCL11 antibody [EPR21755-173] (AB216157)
CXCL11 was immunoprecipitated from 0.35mg of THP-1 (human monocytic leukemia cell line) whole cell lysate with ab216157 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab216157 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/5,000 dilution.
Lane 1 : THP-1 (human monocytic leukemia cell line) treated with 200 ng/ml interferon-gamma (IFN-gamma, ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, then added 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate 10ug (Input).
Lane 2 : ab216157 IP in THP-1 treated with 200 ng/ml interferon-gamma (IFN-gamma, ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, then added 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab216157 in THP-1 treated with 200 ng/ml interferon-gamma (IFN-gamma, ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, then added 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate.
Blocking/Dilution buffer : 5% NFDM/TBST
All lanes:
Immunoprecipitation - Anti-CXCL11 antibody [EPR21755-173] (ab216157)
Predicted band size: 10 kDa
Observed band size: 11 kDa
true
Exposure time: 30s
- WB
Supplier Data
Western blot - Anti-CXCL11 antibody [EPR21755-173] (AB216157)
Blocking/Dilution : 5% NFDM/TBST
The expression profile observed is consistent with what has been described in the literature (PMID : 17142784).
All lanes:
Western blot - Anti-CXCL11 antibody [EPR21755-173] (ab216157) at 1/1000 dilution
Lane 1:
THP-1 (hman monocytic leukemia cell line) whole cell lysate at 10 µg
Lane 2:
THP-1 treated with 200 ng/ml interferon-gamma (IFN-gamma, <a href='/en-us/products/proteins-peptides/recombinant-human-interferon-gamma-protein-active-ab9659'>ab9659</a>) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, then 300 ng/ml Brefeldin A (BFA) was added to the treated cells for 20 hours, whole cell lysate at 10 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 10 kDa
Observed band size: 11 kDa
true
Exposure time: 37s
- WB
Supplier Data
Western blot - Anti-CXCL11 antibody [EPR21755-173] (AB216157)
Blocking/Dilution : 5% NFDM/TBST
All lanes:
Western blot - Anti-CXCL11 antibody [EPR21755-173] (ab216157) at 1/1000 dilution
All lanes:
Human CXCL11 recombinant protein (aa 22-94) at 0.01 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 10 kDa
Observed band size: 9 kDa
true
Exposure time: 15s
Related conjugates and formulations (1)
-
Anti-CXCL11 antibody [EPR21755-173] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The chemokine plays an important role in immune system regulation and inflammation response. It attracts and activates leukocytes including T-cells and natural killer cells driving them to sites of inflammation and injury. CXCL11 is not part of a complex but interacts with other chemokines and cytokines to modulate immune responses. Its expression is upregulated in response to IFN-γ working synergistically with other chemokines like CXCL9 and CXCL10 in inflammatory environments.
Pathways
CXCL11 is integral to the chemotaxis signaling pathway. It influences the migration and activation of immune cells by interacting with the CXCR3 receptor. This pathway shares involvement with proteins such as CXCL10 which also binds to CXCR3 enabling precise directionality and regulation of immune cell movement towards inflammation sites. Additionally CXCL11's participation in the inflammatory response pathway connects it to multiple cellular responses necessary for combating infections.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (3)
Recent publications for all applications. Explore the full list and refine your search
Cell communication and signaling : CCS 23:414 PubMed41039555
2025
Applications
Unspecified application
Species
Unspecified reactive species
Virchows Archiv : an international journal of pathology 486:803-815 PubMed39592484
2024
Applications
Unspecified application
Species
Unspecified reactive species
Translational oncology 14:101199 PubMed34388692
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com